Teva's Budding Blockbuster Drugs Lend Respite From Legal Concerns - Bloomberg
Teva Pharmaceutical to Replace CEO Kare Schultz - WSJ
Teva Pharmaceuticals to pay New York $523 million to settle claims from its role in opioids crisis - ABC News
Price-fixing lawsuit deals another blow to already fragile Teva, experts say | The Times of Israel
Teva Analysts Say Migraine Drug Approval Gives Needed Relief - Bloomberg
Teva Is Facing Adderall Supply Disruptions as Demand for ADHD Drug Soars - Bloomberg
Drugmaker Teva makes $40B bid for rival Mylan
Teva Wins UK Challenge Over Key Novartis Drug Patents (1)
Teva (TEVA) Agrees to $225 Million Texas Opioid Settlement, AG Says - Bloomberg
Teva to Sell Record $5 Billion of Sustainability-Linked Bonds - Bloomberg
Teva Pharmaceuticals found to be responsible for its role in the opioid epidemic in New York State | CNN
Teva Pharmaceuticals Names Kare Schultz As New CEO | Fortune
Activist Investor Jana Partners Takes Stake in Teva, Report Says | Ctech
Teva says its generic Adderall shortage will last another 2 to 3 months (NYSE:TEVA) | Seeking Alpha
Teva Offers Drugs Valued at $23 Billion to End Opioid Suits - Bloomberg
Teva Pharma's Short Sellers Double Down as Legal Woes Drag On - BNN Bloomberg
Teva Pharmaceutical Will Pay Over $4 Billion in Opioid Settlement - Bloomberg
Teva's $15B free drug opioid settlement might be a great deal in the long run: analyst | Fierce Pharma
Teva CEO Calls 'Trough' Revenues Consequence of Patent Expirations - YouTube
Teva Sees Adderall Supply Delays Continuing for 2-3 Months (1)
The Adderall supply squeeze in the US is growing
Teva flags supply constraints to ADHD drug Adderall as demand rises (NYSE: TEVA) | Seeking Alpha
The Difficulties of Cloning a CEO - Bloomberg
Teva's Adderall Shortage Seen Continuing Into March (TEVA) - Bloomberg
